<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470638</url>
  </required_header>
  <id_info>
    <org_study_id>Flt3-L SS</org_study_id>
    <nct_id>NCT01470638</nct_id>
  </id_info>
  <brief_title>A Study of Flt3-Ligand Levels in Sjögrens Syndrome</brief_title>
  <official_title>Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to
      markers for inflammation and degeneration in patients with primary Sjogrens syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for
      inflammation and degeneration in patients with primary Sjogrens syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome</measure>
    <time_frame>June 2009 - June 2015</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sjogrens Syndrome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The rheumatology clinic at Sahlgrenska University hospital, Gothenburg, Sweden
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fulfill the ACR-criteria for primary Sjogrens syndrome,

          -  age above 18 years old

        Exclusion Criteria:

          -  other CNS-disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mats Dehlin, PhD-student</last_name>
    <phone>+46-31-3424173</phone>
    <email>mats.dehlin@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Rheumatology, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Dehlin, PhD student</last_name>
      <phone>+46-31-3424173</phone>
      <email>mats.dehlin@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Mats Dehlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flt3-L</keyword>
  <keyword>CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

